Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum

J Neurosci Res. 2004 Jul 1;77(1):100-7. doi: 10.1002/jnr.20138.

Abstract

Adenosine A(2A) receptor antagonists are being regarded as potential neuroprotective drugs, although the mechanisms underlying their effects need to be better studied. The aim of this work was to investigate further the mechanism of the neuroprotective action of A(2A) receptor antagonists in models of pre- and postsynaptic excitotoxicity. In microdialysis studies, the intrastriatal perfusion of the A(2A) receptor antagonist ZM 241385 (5 and 50 nM) significantly reduced, in an inversely dose-dependent way, the raise in glutamate outflow induced by 5 mM quinolinic acid (QA). In rat corticostriatal slices, ZM 241385 (30-100 nM) significantly reduced 4-aminopyridine (4-AP)-induced paired-pulse inhibition (PPI; an index of neurotransmitter release), whereas it worsened the depression of field potential amplitude elicited by N-methyl-D-aspartate (NMDA; 12.5 and 50 microM). The A(2A) antagonist SCH 58261 (30 nM) mimicked the effects of ZM 241385, whereas the A(2A) agonist CGS 21680 (100 nM) showed a protective influence toward 50 microM NMDA. In rat striatal neurons, 50 nM ZM 241385 did not affect the increase in [Ca(2+)](i) or the release of lactate dehydrogenase (LDH) induced by 100 and 300 microM NMDA, respectively. The ability of ZM 241385 to prevent QA-induced glutamate outflow and 4-AP-induced effects confirms that A(2A) receptor antagonists have inhibitory effects on neurotransmitter release, whereas the results obtained toward NMDA-induced effects suggest that A(2A) receptor blockade does not reduce, or even amplifies, excitotoxic mechanisms due to direct NMDA receptor stimulation. This indicates that the neuroprotective potential of A(2A) antagonists may be evident mainly in models of neurodegeneration in which presynaptic mechanisms play a major role.

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology
  • Adenosine A2 Receptor Antagonists
  • Animals
  • Calcium / metabolism
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Corpus Striatum / physiopathology
  • Dose-Response Relationship, Drug
  • Glutamic Acid / metabolism
  • In Vitro Techniques
  • L-Lactate Dehydrogenase / drug effects
  • L-Lactate Dehydrogenase / metabolism
  • Male
  • Models, Biological
  • N-Methylaspartate / pharmacology
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / physiopathology
  • Neurons / drug effects
  • Neurons / metabolism
  • Neuroprotective Agents / metabolism*
  • Neuroprotective Agents / pharmacology
  • Neurotoxins / antagonists & inhibitors
  • Neurotoxins / metabolism*
  • Phenethylamines / pharmacology
  • Pyrimidines / pharmacology
  • Quinolinic Acid / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A2A / metabolism*
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Synaptic Membranes / drug effects
  • Synaptic Membranes / metabolism*
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Triazines / pharmacology
  • Triazoles / pharmacology

Substances

  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Adenosine A2 Receptor Antagonists
  • Neuroprotective Agents
  • Neurotoxins
  • Phenethylamines
  • Pyrimidines
  • Receptor, Adenosine A2A
  • Receptors, N-Methyl-D-Aspartate
  • Triazines
  • Triazoles
  • ZM 241385
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Glutamic Acid
  • N-Methylaspartate
  • 4-Aminopyridine
  • L-Lactate Dehydrogenase
  • Quinolinic Acid
  • Adenosine
  • Calcium